Valeant Pharmaceuticals International : Medicis Pharmaceutical Dealogic Deal # : 760566
Data as of : 9/4/2012
Target Acquiror Dates & Values
Medicis Pharmaceutical Valeant Pharmaceuticals International
Target: 100 % stake Buying: 100 % stake Rumored 8th Aug 2011 Deal Value $m 2,807.3
NY MRX 60 m shares outstanding Public (Listed) Announced 3rd Sep 2012 Value ex Debt $m 2,807.3
United States Canada
Healthcare Healthcare Expected 4Q 2012 Consideration
Deutsche Bank | Advisor JP Morgan | Advisor Completed -
Roberts Mitani | Advisor Skadden Arps Slate Meagher & Flom | Attorney
Latham & Watkins | Attorney Sullivan & Cromwell | Attorney Withdrawn -
Weil Gotshal & Manges | Attorney
Termination Fee, Target $m tbd
Termination Fee, Acquiror $m tbd
Financials 30th Jun 2012
Balance Sheet Debt/Equity: 1.2
Timeline Events Premiums & Multiples
Initial Offer $44
Current Offer $44
Income Statement
Cash Flows
Operations $m 202
Profitability
Profit Margin 17%
Return on Equity 11%
League Table Impact Sector Trend
2012 YTD Announced Global M&A by Deal Value, $bn Monthly Announced Global M&A, $bn: Healthcare
1 Goldman Sachs 376.9
2 JPMorgan 342.3
3 Morgan Stanley 320.7
4 Deutsche Bank 268.0
5 Credit Suisse 262.4
6 Barclays 259.3
7 Citi 251.2
8 BAML 213.3
9 Rothschild 136.9
10 Nomura 121.7
2012 Dealogic. All rights reserved.